Stereotactic body radiation therapy in non-small-cell lung cancer: linking radiobiological modeling and clinical outcome.
For patients with peripheral, early-stage non-small-cell lung cancer, it has been found feasible to deliver 5 or fewer fractions of large doses through stereotactic body radiation therapy (SBRT) without causing severe early or late injury and with impressive tumor control. In this review, we employ radiobiological modeling with the linear quadratic formulation to explore the adequacy of various dose schedules used for tumor control in the lung as supported by clinical evidence, the influence of dose distribution and delivery time on local control, and how to decrease the likelihood of severe toxicity following SBRT. Furthermore, the validity of the linear quadratic formalism in the high dose range of SBRT for lung cancer is explored.
Chi
Alexander
A
Department of Radiation Oncology, University of Arizona, Tucson, 85724, USA. achiaz2010@gmail.com
Tomé
Wolfgang A
WA
Fowler
Jack
J
Komaki
Ritsuko
R
Nguyen
Nam P
NP
Mehta
Minesh P
MP
Welsh
James S
JS
D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000601:surgery*; D011853:Radiobiology; D016634:Radiosurgery; D016896:Treatment Outcome